Category Archives: Epigenetics

Regrowing a severed head is no problem for sea creatures fittingly called Hydra, and researchers have now mapped exactly how this happens at a genetic level for the first time.

Hydra are a group of small, tree-shaped fish. Unlike mammals, they are loaded up with stem cells that have the unlimited capability to renew themselves, and so are commonly believed to be biologically immortal.

They reproduce asexually in a process called budding, where the offspring grows headfirst from the base of the animal.

Because this is such an uncommon trait, the networks of genes used to regrow entire organs including the head remain largely unexplored.

Now, a team of researchers has found that Hydra regrow severed heads in a very different way to how they bud. It wasnt the types of genes that matter, but how the genes are used a phenomenon known as epigenetics.

Genetic processes are complex. Stem cells can turn into any other cell, depending on which genes are expressed during development.

Get an update of science stories delivered straight to your inbox.

Genomics DNA holds all the information about every gene, but not every gene is expressed in a single cell. Some of the DNA is turned into messenger RNA (mRNA) through a process called transcription, which is then translated into a chain of amino acids. These chains fold into proteins, which are responsible for carrying out work in the cell.

The final cocktail of proteins determines what type of cell the stem cell can turn into.

Both transcription and translation require special regulatory elements to be successful. These elements can also dictate which genes are switched on and off to control the quantity of protein made, which can have a huge effect on the fate of stem cells. This is the driving principle behind epigenetics.

In their study, published in Genome Biology and Evolution, the researchers identified around 13,000 regulatory elements that were remodelled during Hydra head regeneration. These elements switched a small subset of genes on and off differently during head regeneration than at other times, altering the population of proteins that were eventually made.

To illustrate how this works, imagine the cell is like a large production factory. The transcription factors are like managers who instruct the workers on their tasks. They can also tell the workers to divert their work and focus on a different process for a little while. The tools they use never change, but they are now working with different instructions about what to make, and they will product a different product in this case, its a brand-new head.

One exciting finding of this work is that the head regeneration and budding processes in Hydra are quite different, says the papers lead author, Aide Macias-Muoz. Even though the result is the same (a Hydra head), gene expression is much more variable during regeneration.

These findings suggest that complex developmental enhancers were present early in evolution.

Read more from the original source:
Hydra regrow their heads and live forever due to epigenetics - Cosmos Magazine

The Epigenetics in healthcare market was valued at US$ 991.45 million in 2017 and it is projected to reach US$ 2,611.57 million by 2025; it is expected to grow at a CAGR of 13.6% from 2018 to 2025.

According The Insight Partners study on Epigenetics Market Forecast to 2025 COVID-19 Impact and Global Analysis by Product ,Technology, Application, End Users, The report highlights trends existing in the market, and drivers and hindrances pertaining to the market growth. The growth of the Epigenetics in healthcare market is attributed to the declining prices of sequencing, increasing prevalence of cancer and funds & grants provided by government bodies.

The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence is known as epigenetics. A single or multiple change in phenotype without a changing the genotype which results affects the cells that can read the genes.

Get Sample PDF Copy of Epigenetics Market at: https://www.theinsightpartners.com/sample/TIPRE00007157/

Market Insights

Growing Applications of Epigenetics in Healthcare to Drive Epigenetics in Healthcare Market Growth

The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. The costs associated with DNA sequencing performed at the sequencing centers which is funded by the Institutes, has tracked by the National Human Genome Research Institute (NHGRI) for many years. This information has served as a key standard for establishing the DNA sequencing capacity and considering improvements in DNA sequencing technologies of the NHGRI Genome Sequencing Program (GSP).

In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$3.7 billion in 2000 and took 13 years for the completion. However, the costs for the same in recent years has reduces to US$1,000 and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing.

Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.

The study of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, provide insights into tumorigenic pathways, which is located above the genetic code. The microarray and nextgeneration sequencing (NGS) technologies help to detect altered methylation patterns and other epigenetic changes in cancer. For this, Illumina works with the cancer epigenetics experts to ensure its array and NGS solutions to meet the rapidly growing needs of the field.It also includes the impact of the COVID-19 pandemic on the market across all the regions. The sexual wellness, by region, is segmented into North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and South and Central America (SAM).North America held the largest market share in 2021.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Download the Latest COVID-19 Analysis on Epigenetics Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPHE100000971

In terms of product, the Epigenetics in healthcare market is segmented into reagents, kits, enzymes, instruments & consumables and bioinformatics tools. In 2017, the kits segment held a largest market share of 29.8% of the epigenetics market, by product. This segment is also expected to dominate the market in 2025 owing to availability of several kits in the market for the gene expression analysis such as MicroRNA analysis, SNP genotyping analysis and other procedures.

Based on technology, the Epigenetics in healthcare market is segmented into histone modification, dna methylation and others. In 2017, the DNA methylation segment held a largest market share of 51.1% of the epigenetics market, by technology. This segment is also expected to dominate the market in 2025 as the technology mechanistic change in genomic conformation sets out a platform for various cellular processes, such as the exposure of the promoter of a specific gene to its transcriptional machinery.

In terms of application, the Epigenetics in healthcare market is segmented oncology, cardiovascular diseases and others. Oncology segment is anticipated to grow at a CAGR of 13.6% during the forecast period. The epigenetics offers prodigious potential for the identification of biomarkers that can be used to detect and diagnose cancer in its earliest stages.

In terms of end user, the Epigenetics in healthcare market is segmented into academic & research institutes, biotechnology & pharmaceutical companies, and contract research organization. In 2017, the pharmaceuticals & biotechnological companies segment held a largest market share of 61.2% of the epigenetics market, by end user. This segment is also expected to dominate the market in 2025.

Epigenetics Market: Competitive Landscape and Key Developments

Merck KGaA,Thermo Fisher Scientific Inc.,ABCAM Plc,Agilent Technologies,Active Motif,Qiagen,Bio-Rad Laboratories, Inc.,Perkinelmer Inc.,New England Biolabs (NEB),Illumina Inc.

Order a Copy of Epigenetics Market Shares, Strategies and Forecasts 2021-2025 Research Report athttps://www.theinsightpartners.com/buy/TIPHE100000971/

The Epigenetics in healthcare market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone:+1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/epigenetics-market/

Read more:
Epigenetics Market to Garner US$ 2611.57 MN, Globally, by 2025 at 13.6% CAGR: The Insight Partners - Digital Journal

Job descriptionApplications are invited for a Research Assistant or Postdoctoral Research Associate to join the Developmental Epigenetics Group in the Department of Medical and Molecular Genetics. The group focuses on understanding early life events that programme metabolic health for the lifetime. Within this broad topic we study genetic and environmental causes of pregnancy complications, and lifelong effects of an adverse early life environment for the offspring. Our lab integrates mouse genetics, epigenetics, maternal physiology and metabolomics to try to understand programming phenomena at multiple levels. The post-holder will undertake research to build on our existing programme which seeks to understand how adipose stem cells are formed during development, and how they contribute to fat storage over the lifecourse. The group has generated considerable physiological and transcriptomics data from animal models where the process of adipose development is impaired. The post holder will build on these data to validate new candidate pathways and processes, using a combination of bioinformatics, immunohistochemistry, in-vivo physiology and genetic cell labelling approaches.This post will be offered on an a fixed-term contract for 7 monthsThis is a full-time post - 100% full time equivalent.

Key responsibilitiesBoth RA and PDRA Perform experiments to explore gene regulatory networks that define adipose stem cell populations. Present data at regular group meetings within the Department of MMG. Support the training of undergraduate and postgraduate project students. Interact scientifically with other members of the group and departmental colleagues. Contribute to the preparation of manuscripts for journal publication. Plan own day-to-day research activity within the framework of the agreed research schedule; co-ordinate own work with that of others to avoid conflict or duplication of effort; contribute to the planning and implementation of research projects.Research Assistant: Support the technical aspects of the smooth running of the lab Including stock maintenance, reagent preparation and genotyping animal stocks.Research Associate: Take the intellectual lead the project and help drive the laboratory research programme in adipose stem cell biology. Contribute to the integration and collaboration of research project with other branches of the department and with external collaboratorsThe above list of responsibilities may not be exhaustive, and the post holder will be required to undertake such tasks and responsibilities as may reasonably be expected within the scope and grading of the post.Skills, knowledge, and experienceEssential criteria Research Assistant1. Bachelors and/or Masters degree at upper second level or above in a biomedical subject.2. Laboratory experience in molecular techniques.3. Motivated and hard-working4. Ability to learn new techniques/skills on the job5. Ability to integrate with colleagues and work as part of a team6. Ability to work under reduced supervision7. Reliable and conscientious approach to duties8. Willing to undertake share of group tasks9. Experience of previous, self-directed research.Desirable criteria Research Assistant1. Computational programming skills (R, Python or similar)2. Experience with Immunohistochemistry/In vivo physiology/flow cytometry.3. Knowledge of molecular genetics/epigenetics/developmental biology.Essential criteria Research Associate1. PhD awarded in relevant subject area (bioinformatics, genetics, developmental biology, cell biology)2. Laboratory experience in molecular techniques.3. Excellent interpersonal and communication skills, with ability to communicate complex ideas to non-specialists4. Track record of published papers5. Motivated and hard-working6. Ability to learn new techniques/skills on the job7. Ability to integrate with colleagues and work as part of a team8. Ability to work under reduced supervision9. Reliable and conscientious approach to duties10. Willing to undertake share of group tasksDesirable criteria Research Associate1. Computational programming skills (R, Python or similar)2. Experience with Immunohistochemistry/In vivo physiology/flow cytometry.3. Knowledge of molecular genetics/epigenetics/developmental biology.4. HO training for the use of in-vivo models.* Please note that this is a PhD level role but candidates who have submitted their thesis and are awaiting award of their PhDs will be considered. In these circumstances the appointment will be made at Grade 5, spine point 30 with the title of Research Assistant. Upon confirmation of the award of the PhD, the job title will become Research Associate and the salary will increase to Grade 6.Further informationCandidates who are successfully shortlisted based on their application form and CV will be invited to interview, which will include a short presentation to be prepared in advance.This post is subject to Occupational Health clearance

Read more from the original source:
Research Associate or Research Assistant in Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 274309 - Times Higher Education (THE)

Newpath Founding PartnerThomas Cahill, M.D., Ph.D/Courtesy Newpath Partners

A number of scientific entrepreneurs just might get their Christmas, Hanukkah or Kwanza wish this year, as Newpath Partners announced the launch of Fund II, its second in three years.

A majority of the $350 million raised by Newpath will be allocated to companies founded by current academic partners bearing prestigious names such as Ben Cravatt, Ph.D. of theScripps Research Institute, David Liu, Ph.D., at theBroad Instituteof Harvard and MIT and Siddhartha Mukherjee, M.D., Dphil of Columbia University Medical Center.

Companies funded by Newpath in the first fund include gene editing companyPrime Medicine,Chroma Medicine, a new player in the emerging field of epigenetics,Kojin Therapeutics,which is using insights into cell states to tackle cancer and fibrosis andExo Therapeutics, which recently raked in a$78 million Series Bfor its enzyme inhibitors.

Newpath is guided by theethos: Do the right thing and good things will happen." When the COVID-19 pandemic stuck, the firms founding partner Thomas Cahill, M.D., Ph.D., tried to do just that, leading a group called Scientists to Stop Covid 19, a non-partisan coalition of leading researchers that helped to guide government policy to ensure adequate production of vaccine and deployment. Members of this group had no financial conflicts of interest.

It's hard to make decisions when you have so much data, so one of the things we were trying to do is actually flesh out the important, significant information so that we can pass it along to leadership so they could make educated decisions, Cahill told BioSpace. He added that this is the same approach Newpath takes to its portfolio. Its all about mining the data for the best possible idea.

It takes a long time for [scientists] to agree on something. You sit there with a big problem, and four people are saying four different things. A year later, 25% of each of us is right, and now we have a completely different proposal, he said. Cahill himself is a structural biologist who studied under Dr. Robert (Bob) Lefkowitz at Duke University School of Medicine.

The companys investees have been impressed so far.

Newpath Partners is different in every sense,saidStuart Schreiber, Ph.D., a professor at Harvard University and co-founder of the Broad Institute, Kojin and Kisbee Therapeutics, another Newpath company. Many scientists on the doorstep of breakthrough discoveries have found that academia is not the place for their ideas to flourish to have impact in the world. Newpath Partners champions scientists and is committed to translating discoveries into solutions.

The new fund will go toward the development of four new companies. One, Neumora Therapeutics, which is pioneering precision medicines for neuropsychiatric disorders and neurodegenerative diseases, officiallykicked off its journeyin October with $500 million that included a $100 million equity investment fromAmgen. The other three companies remain in stealth mode and are yet to be disclosed.

As for the future, while Cahill said the 2010s were all about oncology, I really think this decade, hopefully, given the need for it, will be about neuropsychology. We really need to disrupt the space. If we just start looking at the brain as another organ and not like a black box, we'll make changes.

Also on Wednesday, M Ventures,Merck KGaAs venture capital arm, closed a new fund of 600 million euros (approximately $677 million USD). The new capital will allow M Ventures to expand its portfolio of innovative companies aligned with Mercks overall strategy.

"Given its extensive expertise in identifying new technologies and capabilities, we aim to increase our annual financial investments. This will enable M Ventures to continue to advance our pioneering innovation strategy, to deliver sustainable business performance and to be a catalyst for innovative companies to develop breakthrough technologies, Merck CEO Beln Garijosaidin a statement.

BioSpace will keep a sharp eye on the investment stemming from both of these funds in 2022!

See the article here:
Newpath Commits $350 Million to Fund the Next Good Things in the Life Sciences - BioSpace

Pune, Maharashtra, December 10 2021 (Wiredrelease) Market.Biz :Market.biz recently released a new research report on the Wind Turbine Market which uncovered accurate information about the long-term prospects of the global and regional market. It has orderly defined the market scenario and highlights the industrial developments with Wind Turbine leading players. Further, It covers the market specifications by chapters and industry procedure that will absolutely help our readers point to the Wind Turbine industry perspective to promote the stability of the cost and revenue structure.

Market Estimations:

The main purpose of this report is to provide readers with factual information about the Wind Turbine market, to help them collect and develop viable strategies based on the general information provided on the website. Detailed market statistics of Wind Turbine reveals the current status, projections, and future classification such as product type, end-use, region, and main industry of Wind Turbine Market. In addition, it sheds light on industry factors such as development, supply, and demand, its current outlook, growth trajectory over the decades, and opportunities for Wind Turbine industry participants around the world. Moreover, the report analyzes business plans, sales, and profits, production volumes and sales, suppliers of raw materials, and buyers of Wind Turbine Industry for information needs and distribution rates.

Get a sample PDF of the report with your company email ID: https://market.biz/report/global-wind-turbine-market-gm/#requestforsample

Note: To get a sample report, you must use your company email address for higher priority.

The Competitive Landscape segment in the Wind Turbine market report is based on the potential of the major players in the current market. This section of the report highlights various important market makers. It helps the user understand the systems and overall effort that the player focuses on when looking for battles. The complete report provides an excellent overview of the Wind Turbine market. Competitive Landscape is based on COMPANY PROFILES, COMPANY OVERVIEW, FINANCIAL HIGHLIGHTS, PRODUCT PORTFOLIO, SWOT ANALYSIS, KEY STRATEGIES, AND DEVELOPMENTS.

The main actors identified in this report are: Goldwind, LEITWIND, Nordex Energy, Senvion, Siemens Wind Power and Renewables, Vestas, Suzlon, ENERCON, GAMESA ELECTRIC, GE Wind Turbines

The report presents a global segmentation of the Wind Turbine market based on product type, end-user, and region. The report provides an analysis of selected market segments from 2016 to 2020 and forecasts for the period from 2021 to 2030. Each segment is calculated in terms of revenue generated (Million USD) and Average Annual Growth Rate (CAGR). In the additional section, the Wind Turbine report provides a market breakdown study of major regions of the world such as North America, Asia-Pacific, Europe, South America, The Middle East, and Africa, and the Rest of the World.

Product Types: Horizontal-Axis Wind Turbine, Vertical-Axis Wind Turbine

Target Applications: Land Wind, Offshore Wind

Buy the latest report here: https://market.biz/checkout/?reportId=607206&type=Single%20User

Imperative Points Covered In The Global Wind Turbine Market Report:

Historical and current market sizing report forms the basis of the global Wind Turbine market and is expected to grow in the future.

Information was given on the competitive environment in the Wind Turbine industry, and this refers to the visibility dashboards of competing companies and their respective market shares by value (in millions of dollars) and volume (in units).

This report analyzes the global Wind Turbine market by product, end-user, and region, and provides a cost forecast (in millions of US dollars) over the next few years.

The global market value of Wind Turbine described in the report is complemented by the collection of data and information for each region.

Report Customization..?:

Yes, a Customized Report is the way to go! Our in-house analysts will be more than capable of collating and packaging all crucial data as per your specific requirements.

Any questions? Ask our expert https://market.biz/report/global-wind-turbine-market-gm/#inquiry

Note: For higher priority, it is recommended to use company or business data.

For more details, kindly get in touch using the credentials mentioned below:

Contact No: +1(857)4450045, +91 9130855334.Email: inquiry@market.biz

Latest Press Release:

Global Printed Cartons Market By Type(Paperboard, Corrugated Board, Kraft Board, Coated Paper, Liquid Board), By Application(Food and Beverage, Hardware and Electronics, Homecare, Healthcare, Cosmetics and Personal Care), By Country, Competition Scenario and Forecast by 2030. Printed Cartons Market Size Is estimated to reach US $ 1,65,570.5 Million By 2030, From US $ 1,23,200. Million in 2020, with the CAGR Of 3% By 2030. https://market.biz/report/global-printed-cartons-market-gm/

Global Rail Equipment Market By Type(Locomotives, Passenger trains, Freight cars, CRH trains, Subway trains), By Application(Grain Growing, Sugar Cane Growing, Black Coal Mining, Iron Ore Mining, Rail Freight Transport, Rail Passenger Transport), By Country, Competition Scenario and Forecast by 2030. Rail Equipment Market Size Is estimated to reach US $ 1,62,983.4 Million By 2030, From US $ 1,23,992.5 Million in 2020, with the CAGR Of 2.8% By 2030. https://market.biz/report/global-rail-equipment-market-gm/

Global Picosecond Lasers Market By Type(<50W, 50-100W, >100W), By Application(Scientific Research and Military, Medical and Aesthetic, Micromachining/Material Processing), By Country, Competition Scenario and Forecast by 2030. Picosecond Lasers Market Size Is estimated to reach US $ 9,831.8 Million By 2030, From US $ 1,231.1 Million in 2020, with the CAGR Of 23.1% By 2030. https://market.biz/report/global-picosecond-lasers-market-gm/

Global Vitreoretinal Surgery Devices Market By Type(Vitreoretinal Packs, Vitrectomy Machines, Photocoagulation Lasers, Illumination Devices, Vitrectomy Probes, Vitreoretinal Surgery Instruments & Kits), By Application(Hospitals, Free Standing Ambulatory Surgery Centers), By Country, Competition Scenario and Forecast by 2030. Vitreoretinal Surgery Devices Market Size Is estimated to reach US $ 1,452.2 Million By 2030, From US $ 1,233. Million in 2020, with the CAGR Of 1.6% By 2030. https://market.biz/report/global-vitreoretinal-surgery-devices-market-gm/

Trending Reports:

How We Can Expect The E-Learning Virtual Reality Market to Grow in The Future, Healthcare Industry Facts and Statistics-Market.Biz https://www.digitaljournal.com/pr/How-We-Can-Expect-The-E-Learning-Virtual-Reality-Market-to-Grow-in-The-Future,-Healthcare-Industry-Facts-and-Statistics-Market-Biz

How We Can Expect The Epigenetics Diagnostic Market to Grow in The Future, Healthcare Industry Facts and Statistics-Market.Biz https://www.digitaljournal.com/pr/How-We-Can-Expect-The-Epigenetics-Diagnostic-Market-to-Grow-in-The-Future,-Healthcare-Industry-Facts-and-Statistics-Market-Biz

How We Can Expect The Essential Oil & Aromatherapy Market to Grow in The Future, Healthcare Industry Facts and Statistics-Market.Biz https://www.digitaljournal.com/pr/How-We-Can-Expect-The-Essential-Oil-&-Aromatherapy-Market-to-Grow-in-The-Future,-Healthcare-Industry-Facts-and-Statistics-Market-Biz

This content has been published by Market.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

See original here:
Wind Turbine Market Development Overview And Analysis Till 2030- Market.Biz - Digital Journal

Cancer Testing Product Market report focused on the comprehensive analysis of current and future prospects of the Cancer Testing Product industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Cancer Testing Product market has been done in order to calculate the growth rates for each segment and sub-segments.

Cancer screening aims to detect cancer before symptoms appear. This may involve blood tests, urine tests, other tests, or medical imaging. The benefits of screening in terms of cancer prevention, early detection and subsequent treatment must be weighed against any harms.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report: https://www.a2zmarketresearch.com/sample-request/516591

Top Key Vendors of this Market are:

Epigenetics Ag, Techlab, Positive Bioscience, Agilent Technologies, Bio-Rad Laboratories, Affymetrix, Genextropy Inc., Abbott Diagnostics, Dias Orin S.P.A, Beckman Coulter, Roche Diagnostics, Fujirebio Diagnostics, Johnson & Johnson, Cardinal Health, M Genomics Ltd, Hologic.

Global Cancer Testing Product Market Segmentation:

Market Segmentation: By Type

Lung, Blood, Bone, Others

Market Segmentation: By Application

Breast cancer, Cervical cancer, Bowel cancer, Prostate cancer, Lung Cancer, Pancreatic cancer, Other cancers

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Cancer Testing Product market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Cancer Testing Product market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Cancer Testing Product market.

Get Special Pricing on this Premium Report: https://www.a2zmarketresearch.com/discount/516591

The influence of the latest government guidelines is also analysed in detail in the report. It studies the Cancer Testing Product markets trajectory between forecast periods. The cost analysis of the Global Cancer Testing Product Market has been performed while keeping in view manufacturing expenses, labour cost, and raw materials and their market concentration rate, suppliers, and price trend.

Reasons for buying this report:

Table of Contents

Global Cancer Testing Product Market Research Report 2021 2027

Chapter 1 Cancer Testing Product Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cancer Testing Product Market Forecast

Buy Exclusive Report: https://www.a2zmarketresearch.com/checkout

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Read more here:
Cancer Testing Product Market to Witness Growth Acceleration | Epigenetics Ag, Techlab, Positive Bioscience Energy Siren - Energy Siren

I stood in front of a book cart that my colleagues and I call recoverymisplaced items that need to be put back in their respective places. I glanced at my watch and read 6:04 p.m. Three more hours until my shift at the local bookstore ended for the day. The store was quiet, except for Mariah Careys All I Want for Christmas Is You playing in the background. A trace of roasted Starbucks coffee beans mixed with the smell of new books lingered in the air.

My mind raced with my plans for the week as I grabbed a book from the cart. Would I be able to catch up on my lectures when I get home? How would I split my studying for my upcoming epigenetics test? When could I start my paper that was due the following Monday? I put the book back where it belonged. What day could I fit a career counselling appointment in my schedule? Did I check-up on my loved ones that day?

I took another book from the cart and paused at the wave of thoughts I was experiencing. The book rested in my hand. The longer I let my thoughts wander, the faster my heart beat, and the more anxious I felt. I hurried to the cash desk, grabbed a piece of receipt paper, and scribbled a quick to-do list. I shoved the paper inside my pocket, let out a sigh of relief, and focused on the book I had been holding titled Good Anxiety: The Power of Harnessing The Most Misunderstood Emotion by Dr. Wendy Suzuki. I smiled.

Ever since watching her famous TED talk, which now has more than seven million views on YouTube, Dr. Suzuki has become an inspiration to me. She is a professor of Neural Science and Psychology in the Center for Neural Science at New York University. She is also an internationally recognized expert on neuroplasticity. Dr. Suzuki was recently named one of the 10 women changing the way we see the world byGood Housekeepingand regularly serves as a sought-after expert for publications includingThe Wall Street Journal,Shape, andHealth, as stated on her website.

When I read more about Dr. Suzukis research and her first book, Healthy Brain, Happy Life: A Personal Program to Activate Your Brain and Do Everything Better, in my first year of undergrad, I became a big fan of her work. I later decided to pursue a specialist in neuroscience at UTM. Now in my third year and after reading Good Anxiety, I had the wonderful opportunity to discuss it with her.

I first asked Dr. Suzuki about the concept of good anxiety. Anxiety and the stress response evolved to protect us, she said. Dr. Suzuki also highlights the importance of shifting ones mindset around anxiety. We need to ask ourselves, how can I make it work for me?

According to her, the first step to having good anxiety is learning how to turn our anxiety levels down. In her book, she mentions that students often reach a level where their performance is impaired due to their high anxiety levels. To avoid reaching this state, Dr. Suzuki suggests breathing deeply using a box breathing technique to naturally activate the bodys parasympathetic nervous system. This technique involves inhaling for four seconds, holding your breath for four seconds, and then exhaling for another four seconds. Its easy to remember and can be used right before youre going to take an exam or before youre going to have a big study session, states Dr. Suzuki. Or in the middle of an anxiety-provoking conversation. Nobody even knows that youre doing it.

Dr. Suzukis second tip is to exercise. Every time you move your body, its like youre giving your brain this wonderful bubble bath of neurochemicals, she adds, explaining that these include serotonin, noradrenaline, dopamine, and endorphins. Studies show that these neurotransmitters immediately improve mood and decrease anxietyeven after just a 10-minute walk. Not only does regular exercise help decrease anxiety, but it also enhances long-term memory and focus, which helps students retain information more easily and for longer periods of time.

I was fascinated by her studies showing that exercise is, as she says, the most transformative thing that you can do for your brain today. She describes that the hippocampus, an area in the brain that is vital for learning and memory, gains brand new brain cells and increases in volume with regular exercise. According to a 2017 study, exercise improves prefrontal cortex function and therefore protects the brain from neurodegenerative disorders like dementia and Alzheimers. Moreover, exercise improves our mood.

Dr. Suzuki and I also discussed the concept of flow. Mihaly Csikszentmihalyi, a Hungarian-American psychologist, describes flow as a state of complete absorption and engagement. In this state, we perform at an optimum level with an almost effortless state of mind. In Good Anxiety, Dr. Suzuki explains micro flow as a shorter, but more frequent flow state that can help us enjoy any experience throughout our day. She describes micro flow as a superpower of anxiety.

After reading more about this, I reflected on the states of micro flow throughout my daymost notably during my neuroplasticity class, where I was fully engaged with my thoughts. Many students can benefit from reflecting on instances of flow or micro flow throughout their week. We can use these to figure out what we are passionate about, which in turn helps us decide what to focus on for our future endeavours.

Inspired by a successful lawyer she met, Dr. Suzuki wrote about turning the what if list of worries that students have into a to-do list. She suggests acting on the worries you can control by looking for coaching, asking a friend to list your best qualities, and getting as much information as you can. For me, I noticed that even scribbling a quick to-do list on a receipt paper at work helped me manage my worries and focus on the present moment.

Dr. Suzukis final message to students emphasizes finding the reasons and joys behind our effort to learn. Everybody right now, take one minute to think about what is joyful to you about the learning that youre doing in this endeavour, she concludes. The joy and the inspiring part is what you get to learn. She advises students to ask themselves what we appreciate in learning. Tell yourself why. Remind yourself why.

Just as Dr. Suzuki inspired me to find my interests, pursue further research in positive neuroplasticity, make the best of my anxiety, and remember my motivation behind choosing further education, I hope she inspires you too. For more information about Dr. Suzuki, her books, and her research, please visit http://www.wendysuzuki.com.

Continued here:
How can students make the best of their anxiety? - The Medium

Not everyone ages gracefully. Thats true for people who dont take care of themselves as adults, but its also true for someone whose health was jeopardized at a young age from contact with something harmful, like air pollution or poor diet. In particular, smoking exposure during early development has been linked with numerous adverse health conditions, and now a new study shows that it, as well as other harmful pollutants, can cause advanced biological aging.

Early life, beginning in the womb through childhood, is a crucial phase in human development where susceptibility to environmental exposures is higher. Changes brought about during this time period can have a lasting effect on a persons metabolism and physiology, thus leading to either good health or diseases later on in life.

Knowing which and why certain exposures are beneficial or detrimental to early development provides evidence for avoidance or increased contact with them. Because aging is a continuous process that occurs at a cellular level throughout life, it can be measured to estimate health risks. One innovative way to measure biological age is through the use of what is known as an epigenetic clock, which measures DNA methylation in specific regions of the genome.

In an analysis led by the Barcelona Institute for Global Health (ISGlobal), researchers investigated the association of over 100 various environmental exposures and the epigenetic clock of 1,000 or more children. What they found was that tobacco smoke, above all, positively correlated with advanced aging.

The epigenetic clock allows us to assess whether someones biological age is older or younger than his or her chronological age, explains author and ISGlobal researcher, Mariona Bustamante.

Biological, or epigenetic, age acceleration has been linked to several age-related conditions like cancer, cellular senescence, mortality, and more. Although DNA methylation is used to calculate epigenetic age, it is just one mechanism by which epigenetics affects gene expression. Histone modifications, chromatin state, and non-coding RNAs can also impact how genes are expressed.

In the past, most epigenetic aging studies have been performed on adults to evaluate environmental exposure, and usually for just one type of exposure. This study was the first to assess a link between early-life exposome of some 83 prenatal and 103 in early childhood exposure with epigenetic age. The results can be found online in the Environment International journal.

While tobacco use stood out as a top factor impacting aging, it was determined that maternal smoking during pregnancy accelerated epigenetic aging during the first years of childhood, as did parental smoking and indoor levels of black carbon (air pollution from partial fuel combustion).

The study also indicated two exposures that proved to have a protective effect against aging. They included the organic pesticide dimethyl dithiophosphate (DMDTP) and a persistent organic pollutant called polychlorinated biphenyl (PCB)-138.

Further research is needed to explain these results, but the former could be due to a higher intake of fruits and vegetables, said first author Paula de Prado-Bert, while the latter could be explained by its correlation with body mass index.

The results regarding smoking are in-line with other studies done on adults. The researchers believe the epigenetic modifications involved here most likely affect similar pathways for immune response, cell cycle, and detoxification, and therefore ultimately impact health from early life onward.

Although the study did have its limitations, like covering all variables of the exposome, it is a start to hopefully more studies that will provide convincing evidence to the dangers of certain toxins on childhood, especially smoking. Aging is a public health issue that everyone should be concerned about. So future research is needed to help drive government policy toward reducing environmental exposures and promote a healthy aging from the very start of life.

Source:Paula de Prado-Bert, et al. (2021).The early-life exposome and epigenetic age acceleration in children. Environment International.

Reference:Exposure to Tobacco Smoke in Early Life is Associated with Accelerated Biological Ageing. Barcelona Institute for Global Health (ISGlobal). August 26, 2021.

See original here:
Epigenetic Study Links Smoke Exposure in Early Life to Advanced Aging - WhatIsEpigenetics.com

Image by the National Cancer Institute on Unsplash

The following post was written and/or published as a collaboration between Benzingas in-house sponsored content team and a financial partner of Benzinga.

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) is developing a novel epigenetics-based treatment that targets the lysine-specific histone demethylase 1 (LSD1) enzyme, which researchers believe plays a key role in the growth of difficult-to-treat cancer cells. Salarius lead drug candidate, seclidemstat, has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration.

As Salarius works toward getting its pioneering new treatment to market as fast as possible, heres what Seclidemstat could mean for sarcoma patients and whats on the horizon for the company.

Sarcoma Patients Struggle with Aggressive Cancers and Limited Treatment Options

Ewing sarcoma is a rare and very deadly cancer that begins in a patients bones and primarily affects children and young adults.

While rare, there are about 500 new cases diagnosed in the United States each year. Of those, 40% will not respond to existing first-line treatments, which include chemotherapy, radiation, and surgery, to remove tumors from the bone. For those who dont see improvements with those first-line treatments or do but then relapse later on, as many as 90% will die within 5 years.

This high mortality rate paired with the fact that Ewing sarcoma primarily affects children and adolescents makes it an urgent priority for cancer researchers around the world.

Other sarcomas, while also rare, feature similar mortality rates and are often equally lacking in effective treatment options. With about 1,500 new cases of myxoid liposarcoma and FET-rearranged sarcomas in the U.S. each year, and a 5-year survival rate ranging from just 16% to 81% depending on how early the cancer was caught, Salarius hopes to get similar regulatory designations to facilitate seclidemstats development for the treatment of other sarcomas as well.

Story continues

As a treatment for Ewing sarcoma alone, Seclidemstat could generate an estimated $200 million in global sales annually, while hoping to significantly improving patient outcomes and quality of life. If approved for myxoid liposarcoma and FET-rearranged sarcoma as well, it could generate an additional $200 million per year.

Salarius Launches new Clinical Trials with Results Anticipated by 2022

Seclidemstat is currently being studied in 2 ongoing clinical trials as part of a treatment combination with chemotherapy agents. Salarius also expanded its clinical programs to study the LSD1 inhibitors potential to treat other sarcomas based on encouraging results from preclinical studies and early clinical trial data.

Going forward, the company is enrolling patients in a slate of new clinical trials set to begin later this year. That includes a clinical trial to study Seclidemstat in combination with Keytruda, an antibody-based drug manufactured by Merck & Co. Inc. (NYSE: MRK) to treat gynecological cancers.

Updates from Salariuss in-progress trials are expected to be announced in the 2nd half of this year with more robust data readouts planned to occur mid-next year. Updates from the trials the company is currently enrolling or planning to initiate soon are expected to be announced by the 2nd half of 2022.

For more information on Salarius, click here.

The preceding post was written and/or published as a collaboration between Benzingas in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

The author of this piece does not hold shares of any of the companies mentioned. Redington, Inc. employees and members of their families may from time own an equity interest in companies mentioned herein.

The preceding article is sponsored by the clinical communications unit of Redington, Inc, which is paid by Salarius Pharmaceuticals to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See the rest here:
Salarius Pharmaceuticals (SLRX) is Developing a Novel LSD1 Inhibitor, Positioning it as a Significant Mover in Epigenetics-Based Cancer Therapies -...

A2Z Market Research announces the release of Epigenetics Diagnostic Market research report. The market is predicted to grow at a healthy pace in the coming years. Epigenetics Diagnostic Market 2021 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market.

The top companies in this report include: Qiagen, Abcam plc, Novartis AG, Thermo Fisher Scientific, Inc., Roche Diagnostics, Eisai Co. Ltd., Active Motif, Merck, Illumina, Inc., Diagenode Diagnostics, Zymo Research Corporation, CellCentric, Valirx, .

Get Sample Report with Latest Industry Trends Analysis: https://www.a2zmarketresearch.com/sample-request/584446

As analytics have become an inherent part of every business activity and role, form a central role in the decision-making process of companies these days is mentioned in this report. In the next few years, the demand for the market is expected to substantially rise globally, enabling healthy growth of the Epigenetics Diagnostic Market is also detailed in the report. This report highlights the manufacturing cost structure includes the cost of the materials, labor cost, depreciation cost, and the cost of manufacturing procedures. Price analysis and analysis of equipment suppliers are also done by the analysts in the report.

This research report represents a 360-degree overview of the competitive landscape of the Epigenetics Diagnostic Market. Furthermore, it offers massive data relating to recent trends, technological advancements, tools, and methodologies. The research report analyzes the Epigenetics Diagnostic Market in a detailed and concise manner for better insights into the businesses.

The report, with the assistance of nitty-gritty business profiles, project practicality analysis, SWOT examination, and a few different insights about the key organizations working in the Epigenetics Diagnostic Market, exhibits a point-by-point scientific record of the markets competitive scenario. The report likewise displays a review of the effect of recent developments in the market on markets future development prospects.

Global Epigenetics Diagnostic Market Segmentation:

Market Segmentation: By Type

ReagentsKitsInstrumentsEnzymesServices

Market Segmentation: By Application

OncologNon-oncology

Geographic analysis:

The global Epigenetics Diagnostic market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

Get Exclusive Discount on this Premium Report: https://www.a2zmarketresearch.com/discount/584446

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Epigenetics Diagnostic Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Epigenetics Diagnostic refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Epigenetics Diagnostic market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Epigenetics Diagnostic makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Epigenetics Diagnostic inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Related Reports:

Travel and Expense Management Software Market Witness Stunning Growth By 2028 | Chrome River Technologies, Trippeo Technologies, Basware

Residential Router Market Future Growth Outlook 2021-2028 | TP-Link, D-Link, Tenda

Scale-out NAS Market to Witness Rapid Growth by 2028 | Dell, HPE, Nasuni

Energy Trading & Risk Management Market to Witness Robust Expansion by 2028 | OpenLink, Triple Point, Accenture

Event Management Software Market Past Research, Deep Analysis and Present Data With Eventbrite (US), Cvent (US), XING Events (Germnany)

Read this article:
Epigenetics Diagnostic Market to Witness Growth Acceleration | Qiagen, Abcam plc, Novartis AG, Thermo Fisher Scientific IMIESA - IMIESA